Abstract
This communication reports the results of two studies aimed at improving the immunosuppressive efficacy of azathioprine in renal transplant patients. Although azathioprine has been used in transplantation for over 30 years, the mechanism of its cytotoxicity is not yet completely defined. It is generally accepted that its principal mode of action involves rapid conversion in vivo to 6-mercaptopurine (6MP), which is further metabolised via 6-thioinosinic acid to cytotoxic thioguanine nucleotides (1). The efficacy of 6MP is reduced by catabolic pathways, one of them being via xanthine oxidase (XO), which oxidises 6MP to thiouric acid. Thus the therapeutic combination of azathioprine with allopurinol, which inhibits the XO path, is usually contra-indicated, having been associated with bone marrow toxicity (2). The importance of this catabolic route is illustrated by the severe myelotoxicity reported in an XO-deficient patient treated with azathioprine (3). Azathioprine and 6MP catabolism may also occur via aldehyde oxidase (AO) and thiopurine methyltransferase (TPMT) (Figure 1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
W.N. Kelley, F.M. Rosenbloom, J.E. Seegmiller, Effects of azathioprine on purine synthesis in clinical disorders of purine metabolism, J. Clin. Invest.. 46: 1518 (1967).
V.G. Raman, V.L. Sharman, H.A. Lee, Azathioprine and allopurinol: a potentially dangerous combination, J. Intern. Med. 228: 69 (1990).
G. Hillebrand, S. Reiter, Hypourikämie — ein differentialdiagnostisches Problem, Internist 32: 226 (1991).
P.R. Chocair, J.A. Duley, H.A. Simmonds, J.S. Cameron, The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53: 1051 (1992).
G.P. Bassadonna, A.J. Matas, K.J. Gillingham, W.D. Payne, D.L. Dunn, D.E.R. Sutherland, P.F. Gores, R.W.G. Gruessner, J.S. Najarian, Early versus late acute renal allograft rejection: impact on chronic rejection, Transplantation 55: 993 (1993).
A.H. Chalmers, P.R. Knight, M.R. Atkinson, 6-Thiopurines as substrates of purine oxidases: a pathway for conversion of azathioprine into 6-thiouric acid without release of 6-mercaptopurine, Aust. J. Exp. Med. Sci. 47: 263 (1969).
K.A. Nath, Reactive oxygen species and renal injury, in: “International Yearbook of Nephrology”, V.E. Andreucci, L.G. Fine, eds., Kluwer Academic, N.Y. (1991).
J.W. Slaton, K.A. Kropp, J.S. Jhunjhunwala, S.H. Selman, Cyclosporin versus azathioprine: a 5-year followup of 200 consecutive cadaver renal transplant recipients, J. Urol. 151: 582(1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chocair, P.R. et al. (1995). Does Low-Dose Allopurinol, with Azathioprine, Cyclosporin and Prednisolone, Improve Renal Transplant Immunosuppression?. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_44
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive